Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Patient Access Advocacy for BTK Inhibitors

The Inflation Reduction Act: Implications for Patient Access in CL

Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

Decision-Making in CLL: The Role of Real-World Evidence

Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

Optimizing Therapy Sequencing in CLL

Empowering Patients: Key Considerations for BTK Inhibitor Adherence

Exploring the Efficacy and Safety of Ibrutinib and Venetoclax in CLL

Dr Ann LaCasce Discusses Potentially Game-Changing Treatments for Lymphoma

Dr Ann LaCasce Looks to the Year Ahead in the Lymphoma Treatment Landscape

Dr Jennifer Brown Discusses Zanubrutinib Uptake in CLL, SLL